On August 17, 2020 JW Therapeutics, the JV formed by Seattle’s CAR-T specialist Juno Therapeutics and China’s WuXi AppTec, reported that it has posted its prospectus for a Hong Kong IPO (Press release, JW Therapeutics, AUG 17, 2020, View Source [SID1234563828]). The company will bring Juno’s CAR-T cell therapies to China, but it has expanded to include immunotherapy in-licensings from other companies as well. Last month, JW acquired Syracuse Biopharma, a Hong Kong cell therapy company. And the prospectus reveals JW will also acquire China rights to off-the-shelf natural killer cell therapy candidates from Taiwan’s Acepodia. JW is expected to raise between $200 million and $300 million in the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!